Beranda › Kanker Ovarium › Oregon › Eugene
Uji klinis Kanker Ovarium di Eugene, OR
9 studi untuk Kanker Ovarium mencari peserta di lokasi sekitar Eugene (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Menerima pesertaFase 2
- Site 0316 - Willamette Valley Cancer Institute/Oncology Associates of Oregon, Eugene
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Menerima pesertaFase 2
- Oncology Associates of Oregon, P.C. /ID# 275006, Eugene
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Menerima pesertaFase 2
- Willamette Valley Cancer Institute and Research Center /ID# 277714, Eugene
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Menerima pesertaFase 3
- USO - Oncology Associates of Oregon, P. C., Eugene
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Menerima pesertaFase 3
- Oncology Associates of Oregon, P.C., Eugene
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Menerima pesertaFase 3
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8010), Eugene
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Menerima pesertaFase 1/2
- USOR Oncology Associates of Oregon, P.C., Eugene
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Menerima pesertaFase 2/3
- Oncology Associates of Oregon, P.C., Eugene
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Menerima pesertaFase 2
- 517, Eugene
Uji klinis Kanker Ovarium di kota lain
- Houston, TX89 studi
- New York City, NY69 studi
- Boston, MA61 studi
- Los Angeles, CA50 studi
- Nashville, TN49 studi
- Arlington, VA46 studi
- Philadelphia, PA44 studi
- Columbus, OH39 studi
- St. Louis, MO38 studi
- Chicago, IL36 studi
- San Antonio, TX31 studi
- Cleveland, OH30 studi
Studi lain di Eugene
- Kanker Paru Non-Sel Kecil13 studi
- Kanker Endometrium8 studi
- Kanker Payudara7 studi
- Leukemia Limfositik Kronis6 studi
- Mieloma Multipel6 studi
- Kanker Metastatik6 studi
- Kanker (semua jenis)6 studi
- Penggunaan Obat dan Kecanduan5 studi
- Kanker Paru5 studi
- Degenerasi Makula5 studi
- Obesitas4 studi
- Kanker Prostat3 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.